EBMT-EHA CAR-T 2019 | The promise of CAR T-cell therapy in hematological malignancies
Emanuele Ostuni
• 26 Apr 2019
CAR T-cell therapy is fascinating due to its potential in the treatment of human hematological malignancies. Here, Emanuele Ostuni, PhD, from Norvartis Oncology, Basel, Switzerland, shares his views on the promising aspects of CAR T-cell therapy. This video was recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
